Shanghai Heartcare Medical Technology Corp. Ltd. Class H (HK:6609)
:6609
Want to see HK:6609 full AI Analyst Report?
Top Page
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
(6609)
Select Model
Select Model
Rating:70Outperform
Price Target:
HK$60.00
▲(9.89% Upside)
Action:UpgradedDate:05/02/26
The score is driven primarily by improved financial performance in 2025 (profitability and free-cash-flow turn positive with low leverage), tempered by the recent history of losses and cash-flow volatility. Technicals are mixed with only modest momentum, and valuation (P/E ~22.4) looks moderate without a stated dividend yield.
Positive Factors
2025 Profitability Turnaround
The sharp 2025 inflection to healthy gross and operating margins and positive free cash flow indicates the business can convert revenue into cash and profit. If sustained, these margins support reinvestment, debt-light growth and resilience vs. competitors over coming years.
Negative Factors
Recent Loss History
The firm's profitability is a recent development after multiple loss-making years. This history raises the risk that margins and cash generation are cyclical or execution-dependent, so sustaining the 2025 profit profile requires consistent execution and demand stability.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Profitability Turnaround
The sharp 2025 inflection to healthy gross and operating margins and positive free cash flow indicates the business can convert revenue into cash and profit. If sustained, these margins support reinvestment, debt-light growth and resilience vs. competitors over coming years.
Read all positive factors
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.05B
Dividend YieldN/A
Average Volume (3M)127.28K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue Growth47.07%
EPS GrowthN/A
CountryHK
Employees344
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.12
Shares Outstanding31,565,804
10 Day Avg. Volume119,990
30 Day Avg. Volume127,280
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.61
Price to Sales (P/S)4.58
P/FCF Ratio13.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.74
Revenue Forecast (FY)HK$541.30M
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices worldwide. The company offers ischemic stroke thrombectomy, intracranial stenosis treatme...
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
84
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 334.94M | 397.72M | 277.90M | 232.34M | 183.03M | 90.09M |
| Gross Profit | 226.03M | 275.70M | 181.72M | 151.79M | 124.33M | 54.95M |
| EBITDA | 22.90M | 50.46M | 21.87M | -68.50M | -167.31M | -183.34M |
| Net Income | 42.44M | 81.18M | -13.62M | -94.01M | -200.38M | -194.22M |
Balance Sheet | ||||||
| Total Assets | 1.25B | 1.29B | 1.21B | 1.20B | 1.31B | 1.50B |
| Cash, Cash Equivalents and Short-Term Investments | 718.20M | 786.81M | 713.72M | 721.14M | 870.12M | 1.22B |
| Total Debt | 45.91M | 42.74M | 35.75M | 36.38M | 50.69M | 41.94M |
| Total Liabilities | 137.78M | 133.50M | 144.00M | 125.60M | 147.08M | 132.10M |
| Stockholders Equity | 1.11B | 1.13B | 1.06B | 1.08B | 1.17B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 30.56M | 139.98M | -8.39M | -137.72M | -304.01M | -260.33M |
| Operating Cash Flow | 41.60M | 154.14M | -3.23M | -88.41M | -266.77M | -205.85M |
| Investing Cash Flow | -194.07M | -253.09M | 10.80M | -125.45M | 44.84M | -161.10M |
| Financing Cash Flow | -11.15M | -44.73M | -12.38M | -21.48M | -24.75M | 821.25M |
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis
Positive
54.60
Price Trends
47.56
Positive
49.66
Positive
51.93
Positive
Market Momentum
2.86
Negative
65.49
Neutral
56.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6609, the sentiment is Positive. The current price of 54.6 is above the 20-day moving average (MA) of 49.69, above the 50-day MA of 47.56, and above the 200-day MA of 51.93, indicating a bullish trend. The MACD of 2.86 indicates Negative momentum. The RSI at 65.49 is Neutral, neither overbought nor oversold. The STOCH value of 56.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6609.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$2.05B | ― | 4.22% | ― | 47.07% | ― | |
68 Neutral | HK$8.64B | 16.88 | 4.02% | ― | 5.10% | -32.48% | |
59 Neutral | HK$3.28B | 73.09 | 2.04% | ― | 91.69% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$3.92B | -6.84 | -11.27% | ― | 16.35% | 9.43% | |
43 Neutral | HK$771.77M | -0.88 | -21.05% | ― | -34.96% | 42.74% | |
42 Neutral | HK$3.02B | -1.03 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
52.90
24.90
88.93%
HK:9996
Peijia Medical Ltd.
5.84
0.62
11.88%
HK:1302
LifeTech Scientific Corporation
2.00
0.45
29.03%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.37
-1.88
-44.24%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.80
1.43
22.45%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.75
-0.67
-27.69%
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events
Shanghai HeartCare Proposes New Articles to Align With Paperless Listing Rules
Apr 27, 2026
Shanghai HeartCare Medical Technology Corporation Limited has proposed amendments to its articles of association to align with updated regulatory requirements, particularly those related to the further expansion of Hong Kong’s paperless list...
Shanghai HeartCare Calls 2025 AGM and Seeks Broad Share Issuance Mandate
Apr 27, 2026
Shanghai HeartCare Medical Technology Corporation Limited has called its 2025 annual general meeting for 28 May 2026 in Shanghai to review standard annual matters, including the 2025 board work report, profit distribution plan, audited financial s...
Shanghai HeartCare Swings to Profit on Rapid Neurovascular Device Growth in 2025
Mar 26, 2026
Shanghai HeartCare reported strong growth for 2025, with revenue rising 46.9% year-on-year to RMB408.3 million and gross margin improving to 70.9%. The company swung to a net profit of RMB83.3 million from a loss a year earlier, as operational eff...
Shanghai HeartCare Schedules Board Meeting to Approve 2025 Results and Consider Dividend
Mar 16, 2026
Shanghai HeartCare Medical Technology Corporation Limited has scheduled a board meeting for March 26, 2026, to review and approve the annual results for the financial year ended December 31, 2025. The board will also consider proposing a final div...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.